Genmab has initiated a share buy-back program, a move that is eliciting confidence from its board of directors. Analysts are positing Genmab as one of the best healthcare stocks to invest in currently, appreciating its strong performance in an otherwise erratic sector. The company suffered a slight setback with a lawsuit from biopharmaceutical company, AbbVie, and the decision by J&J to opt out of a licensing deal; however, its share prices held steady thanks to positive trial results. Despite recent challenges, investment pundits are largely positive about the company's future, with JPMorgan citing the company as having huge upside potential. In other respects, the company has been consistent in issuing stock units and warrants to its staff as a form of incentive. Genmab's recently published annual report for 2024 offers a positive outlook for 2025, despite the fact that J&J’s decision on a key partnership is yet to be made.
Genmab Stocks News Analytics from Sat, 11 May 2024 13:45:28 GMT to Thu, 27 Mar 2025 13:03:24 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor -4
